NCT07069413

Brief Summary

This rigorous randomized controlled trial will evaluate the efficacy and acceptability of a preemptive, telehealth intervention (tele-ImPACT) in a large, representative sample of infant siblings of autistic children, who are known to be at high likelihood of receiving a future diagnosis of autism and/or developmental language disorder (HL-Sibs). If our hypotheses are supported, this innovative and interdisciplinary study will provide empirical support for a novel approach to treatment that is theoretically motivated and developmentally informed, as well as accessible for and acceptable to families, and will lend new insights into the developmental windows in which, mechanisms by which, and subgroups for which the treatment works. Such findings would have strong implications for research, policy, theory, and practice in young children at risk for autism and/or language disorder.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P50-P75 for not_applicable

Timeline
69mo left

Started Apr 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress6%
Apr 2026Mar 2032

First Submitted

Initial submission to the registry

June 30, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

July 16, 2025

Completed
9 months until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2031

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2032

Last Updated

June 12, 2026

Status Verified

June 1, 2026

Enrollment Period

5 years

First QC Date

June 30, 2025

Last Update Submit

June 9, 2026

Conditions

Keywords

autism

Outcome Measures

Primary Outcomes (3)

  • Child Social Communication

    A single z-score average of two scales: VABS socialization standard score (0-100) and ADOS-2 reflected social affect calibrated severity score (inverse coded 1-10). High scores indicate great social communication skills.

    9 months

  • Child Receptive Language

    A single z-score average of two scales: MSEL receptive scaled score (20-80) and VABS expressive scaled score (1-24). With higher scores indicating greater receptive language ability.

    9 months

  • Child Expressive Language

    A single z-score average of two scales:MSEL expressive scaled score (20-80), VABS expressive scaled score (1-24). With higher scores indicating greater expressive language skills.

    9 months

Study Arms (2)

Business as Usual

NO INTERVENTION

Control arm where participants will receive community treatments, as usual.

tele-ImPACT

EXPERIMENTAL

Participants will receive 12 weeks of intervention

Behavioral: tele-ImPACT

Interventions

tele-ImPACTBEHAVIORAL

Participants will receive 12 weeks of Project ImPACT intervention as delivered via Telehealth

tele-ImPACT

Eligibility Criteria

Age6 Months - 24 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • chronological age between 6-24 months
  • has at least one older biological sibling diagnosed with autism

You may not qualify if:

  • adverse neurological history
  • primary sensory deficit (hearing or visual impairment)
  • pre-term birth (gestation \<37 weeks)
  • pre-existing diagnosis of autism or language delay

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

VUMC

Nashville, Tennessee, 37232, United States

RECRUITING

Little Longhorn Lab

Austin, Texas, 78712, United States

RECRUITING

MeSH Terms

Conditions

Autistic Disorder

Condition Hierarchy (Ancestors)

Autism Spectrum DisorderChild Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Central Study Contacts

Lauren Hampton, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
All outcomes assessment ratings will be conducted by an assessor naive to treatment condition. All assessments will be administered by an assessor also naive to treatment condition.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

June 30, 2025

First Posted

July 16, 2025

Study Start

April 1, 2026

Primary Completion (Estimated)

March 31, 2031

Study Completion (Estimated)

March 31, 2032

Last Updated

June 12, 2026

Record last verified: 2026-06

Locations